Division of Cardiology, Lehigh Valley Health Network, Allentown, Pennsylvania.
Division of Cardiology, Lehigh Valley Health Network, Allentown, Pennsylvania.
Heart Rhythm. 2018 May;15(5):708-715. doi: 10.1016/j.hrthm.2018.01.006. Epub 2018 Jan 6.
Limited data are available regarding true estimates of individual complications contributing to readmissions after cardiac implantable electronic device (CIED) implantation.
The purpose of this study was to identify predictors of 30-day readmission in patients admitted for CIED implantation.
The study cohort consisted of patients who underwent CIED implantation in 2014, identified from the National Readmission Database. Readmission was defined as a subsequent hospital admission within 30 days after the discharge day of index admission. If patients had more than 1 readmission within 30 days, only the first readmission was included.
Our final cohort consisted of 70,223 cases, 61,738 (88%) in the no-readmission group and 8485 patients (12%) in the readmission group. Female gender (odds ratio [OR] 1.09; 95% confidence interval [CI] 1.04-1.14; P = .001), atrial fibrillation/flutter (OR 1.23; 95% CI 1.17-1.29, P <.001), acute renal failure (OR 1.65; 95% CI 1.56-1.74; P <.001), coronary artery disease (OR 1.09; 95% CI 1.03-1.14; P = .002), length of stay (OR 1.70; 95% CI 1.51-1.89; P <.001), device placement on the day of admission (OR 0.87; 95% CI 0.80-0.95, P = .001), and fourth quartile of hospital procedure volume (OR 0.91; 95% CI 0.84-0.99; P = .03; first quartile of hospital procedure volume as reference) were independent predictors of 30-day readmissions. The 30-day readmission resulted in additional median charges of $30,692 per patient. Device-related complications were seen in 10.7% of readmitted patients. The most common complications were mechanical (2.8%) and infectious (2.6%).
Several patient and hospital-related factors were identified to be independent predictors of 30-day readmission, accounting for increased health care cost.
关于导致心脏植入式电子设备 (CIED) 植入后再入院的个体并发症的真实估计数据有限。
本研究的目的是确定因 CIED 植入而入院的患者在 30 天内再入院的预测因素。
研究队列由 2014 年接受 CIED 植入的患者组成,这些患者是从国家再入院数据库中确定的。再入院定义为索引入院出院后 30 天内的后续住院。如果患者在 30 天内有多次再入院,仅纳入首次再入院。
我们的最终队列包括 70223 例病例,61738 例(88%)为无再入院组,8485 例(12%)为再入院组。女性(比值比 [OR] 1.09;95%置信区间 [CI] 1.04-1.14;P =.001)、心房颤动/扑动(OR 1.23;95% CI 1.17-1.29,P<.001)、急性肾衰竭(OR 1.65;95% CI 1.56-1.74;P<.001)、冠状动脉疾病(OR 1.09;95% CI 1.03-1.14;P =.002)、住院时间(OR 1.70;95% CI 1.51-1.89;P<.001)、入院当日设备放置(OR 0.87;95% CI 0.80-0.95,P =.001)和医院手术量第四四分位数(OR 0.91;95% CI 0.84-0.99;P =.03;以医院手术量第一四分位数为参考)是 30 天再入院的独立预测因素。30 天再入院导致每位患者的中位数费用增加了 30692 美元。在再入院患者中发现了 10.7%的与设备相关的并发症。最常见的并发症是机械性(2.8%)和感染性(2.6%)。
确定了一些与患者和医院相关的因素是 30 天再入院的独立预测因素,这些因素导致了医疗保健成本的增加。